Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells 3,638 Shares of Stock

Key Points

• DexCom EVP Jereme Sylvain sold 3,638 shares at an average price of $83.27, totaling approximately $302,936. The transaction, conducted under a pre-arranged Rule 10b5-1 plan, reduced his direct ownership by 2.42% to 146,828 shares.
• DXCM shares rose 2.0% to $84.68, while DexCom reported quarterly earnings of $0.70 per share and revenue of $1.31 billion, exceeding analyst estimates. Revenue increased 13.1% year over year.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $88.71; institutional investors own 97.75% of DexCom’s outstanding shares.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Jereme Sylvain sold 3,638 shares of DexCom stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total transaction of $302,936.26. Following the transaction, the executive vice president directly owned 146,828 shares of the company's stock, valued at $12,226,367.56. The trade was a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Trading Up 2.0%

DXCM stock traded up $1.65 during mid-day trading on Monday, reaching $84.68. 2,493,694 shares of the stock traded hands, compared to its average volume of 5,119,560. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. DexCom, Inc. has a one year low of $54.11 and a one year high of $92.59. The stock has a market capitalization of $31.95 billion, a PE ratio of 33.47, a PEG ratio of 1.39 and a beta of 1.42. The business has a 50-day moving average price of $82.75 and a two-hundred day moving average price of $72.80.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same quarter last year, the business earned $0.48 EPS. The business's revenue was up 13.1% on a year-over-year basis. Equities research analysts expect that DexCom, Inc. will post 2.64 EPS for the current year.

Analysts Set New Price Targets

DXCM has been the subject of several recent analyst reports. Weiss Ratings upgraded DexCom from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded DexCom from a "hold" rating to a "buy" rating in a report on Sunday, September 6th. Wells Fargo & Company raised their price target on DexCom from $85.00 to $90.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. Bank of America dropped their price objective on DexCom from $100.00 to $80.00 and set a "buy" rating for the company in a report on Monday, May 18th. Finally, Stifel Nicolaus set a $95.00 price objective on DexCom and gave the company a "buy" rating in a research report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $88.71.

Institutional Trading of DexCom

Several institutional investors and hedge funds have recently modified their holdings of the stock. Reflection Asset Management bought a new position in DexCom in the fourth quarter worth approximately $25,000. Ascentis Independent Advisors purchased a new stake in shares of DexCom in the 1st quarter worth $25,000. MCF Advisors LLC purchased a new stake in shares of DexCom in the 4th quarter worth $32,000. Wellington Grp LLC grew its position in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company's stock worth $34,000 after buying an additional 475 shares in the last quarter. Finally, Cassaday & Co Wealth Management LLC bought a new position in shares of DexCom during the 1st quarter worth $44,000. Institutional investors own 97.75% of the company's stock.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company's products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.